Literature DB >> 15838109

Activins and inhibins and their signaling.

Wylie Vale1, Ezra Wiater, Peter Gray, Craig Harrison, Louise Bilezikjian, Senyon Choe.   

Abstract

Activins and inhibins, which were discovered by virtue of their abilities to stimulate or inhibit, respectively, the secretion of FSH, are members of the transforming growth factor-beta (TGFbeta) superfamily and exert a broad range of effects on the diffentiation, proliferation and functions of numerous cell types. Activins interact with two structurally related classes of serine/threonine kinase receptors (type I and type II). Inhibin antagonizes activin by binding to the proteoglycan, betaglycan, and forming a stable complex with and, thereby, sequestering type II activin receptors while excluding type I receptors. If betaglycan is present, inhibin can also antagonize those bone morphogenic proteins (BMPs) whose signaling is dependent upon access to type II activin receptors. Recent insights regarding the structures of ligands, receptors and their signaling complexes are providing the basis for the development of therapeutics capable of modulating fertility and numerous pathophysiologic processes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15838109     DOI: 10.1196/annals.1315.023

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  21 in total

Review 1.  Discovery and therapeutic promise of selective androgen receptor modulators.

Authors:  Jiyun Chen; Juhyun Kim; James T Dalton
Journal:  Mol Interv       Date:  2005-06

2.  Towards a cure for Fibrodysplasia ossificans progressiva.

Authors:  Gonzalo Sanchez-Duffhues; David J J de Gorter; Peter Ten Dijke
Journal:  Ann Transl Med       Date:  2016-10

3.  Expression profiling of transforming growth factor beta superfamily genes in developing orofacial tissue.

Authors:  Partha Mukhopadhyay; Robert M Greene; M Michele Pisano
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2006-07

Review 4.  Bone turnover across the menopause transition : The role of gonadal inhibins.

Authors:  Kristy M Nicks; Tristan W Fowler; Nisreen S Akel; Daniel S Perrien; Larry J Suva; Dana Gaddy
Journal:  Ann N Y Acad Sci       Date:  2010-03       Impact factor: 5.691

5.  In vivo disruption of TGF-beta signaling by Smad7 leads to premalignant ductal lesions in the pancreas.

Authors:  Chenzhong Kuang; Yan Xiao; Xubao Liu; Teresa M Stringfield; Shaobo Zhang; Zhenzhen Wang; Yan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-27       Impact factor: 11.205

6.  Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1.

Authors:  Brian M Necela; Weidong Su; E Aubrey Thompson
Journal:  J Biol Chem       Date:  2008-09-03       Impact factor: 5.157

Review 7.  Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin.

Authors:  Kristy M Nicks; Daniel S Perrien; Nisreen S Akel; Larry J Suva; Dana Gaddy
Journal:  Mol Cell Endocrinol       Date:  2009-07-15       Impact factor: 4.102

8.  Activin-A in myometrium: characterization of the actions on myometrial cells.

Authors:  Pasquapina Ciarmela; Ezra Wiater; Wylie Vale
Journal:  Endocrinology       Date:  2008-01-31       Impact factor: 4.736

9.  Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment.

Authors:  A D Anastasilakis; S A Polyzos; P Makras; A Gkiomisi; M Savvides; A Papatheodorou; E Terpos
Journal:  Osteoporos Int       Date:  2012-11-03       Impact factor: 4.507

10.  Inhibin and the regulation of bone mass.

Authors:  Dana Gaddy
Journal:  Curr Osteoporos Rep       Date:  2008-06       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.